🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05397405
Recruiting Not applicable

Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome

NCT05397405 · tracked via the Priya Life Science China tracker
Sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Not applicable
Started
2022-05-23
Last updated
2026-04-15

Condition(s) studied

Intracranial Artery Stenosis

Investigational drug(s) / intervention(s)

PCSK9 inhibitor

PCSK9 inhibitor: The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months

Study summary

sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥18 years 2. Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment 3. low density lipoprotein cholesterol \> 70mg/dl (1.8mmol/L) 4. Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained. 5. Lipid-lowering indications of statins 6. Signed an approved informed consents Exclusion Criteria: 1. Contraindications to statins 2. There are contraindications to MRI examination or cannot accept MRI examination 3. Stenosis caused by vasculitis, arterial dissection and moyamoya disease 4. Patients with active bleeding or obvious bleeding tendency 5. Severe heart, lung, renal insufficiency, malignant tumor or other malignant diseases, and death is highly likely within 7 days; pregnancy or women who are lactating 6. Uncontrolled severe diabetes and hypertension 7. Other conditions inappropriate for inclusion judged by investigators

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Nanjing First Hospital, Nanjing Medical University Nanjing Jiangsu Recruiting
Nanjing First Hospital Nanjing Jiangsu Recruiting

More Nanjing First Hospital, Nanjing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05397405 on ClinicalTrials.gov ↗ ← All trials in China